TEVA Stock Analysis: Buy, Sell, or Hold?
TEVA - Teva Pharmaceutical Industries Limited American Depositary Shares
$34.64
1.20 (3.59%)
▲
5d:
+3.03%
30d:
+4.72%
90d:
+14.51%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Jul 29, 2026
24d
Get Alerted When TEVA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TEVA shows positive signals but monitor for confirmation. Market pricing in 1.6% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: TEVA shows positive signals but monitor for confirmation. Market pricing in 1.6% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$64.16
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$39.84
13.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TEVA is currently trading at $34.64, which is considered extended relative to its 30-day fair value range of $32.86 to $34.62. The stock's valuation (Forward PE: 11.2) is in line with its historical norms (10.7). At these levels, the market is pricing in 1.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TEVA is in a uptrend. The price is approaching resistance at $34.92. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: TEVA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $40.90 (+18.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TEVA is in a uptrend. The price is approaching resistance at $34.92. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: TEVA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $40.90 (+18.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$32.86 -
$34.62
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
65.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.6%)
- BULLISH: Trading below Wall St target ($40.90)
- NEUTRAL: Market pricing in 1.6% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$32.86 -
$34.62
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$30.80
Resistance Level
$34.92
Current Trend
Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.25
Wall Street Target
$40.90
(+18.1%)
Revenue Growth (YoY)
2.3%
Earnings Growth (YoY)
72.2%
Profit Margin
9.0%
Valuation Premium vs History
+1.6% premium
PE vs Historical
11.3 vs 10.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.6%
(market-implied from PE analysis)
1-Year Target
$35.19
(+2%)
2-Year Target
$35.76
(+3%)
3-Year Target
$36.33
(+5%)
3-Yr Target (if PE normalizes)
(PE: 11→11)
PE COMPRESSION
$34.56
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 38.5%)
$178.16
(+414%)
Base:
(SPY PE: 11.2, Growth: 38.5%)
$92.02
(+166%)
Bear:
(PE: 9.6, Growth: 38.5%)
$78.22
(+126%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (25x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 24.96 | Current EPS (TTM): $1.34
Bull Case
$73.57
(+112%)
Analyst growth 100.0%, PE expands to 27.5
Base Case
$66.88
(+93%)
Market implied 100.0%, PE stable at 25.0
Bear Case
$22.74
(-34%)
Severe decline -20.0%, PE contracts to 21.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 04, 2026 12:38 AM ET
Data refreshes hourly during market hours. Next update: 1:38 AM
Data refreshes hourly during market hours. Next update: 1:38 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TEVA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Mark Sabag
SELL
62102 shares
2026-03-17
Brian Savage
SELL
1127 shares
2026-03-05
Christine Fox
SELL
7924 shares
2026-03-05
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 62 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 63 BUY |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 61 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 54 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 60 HOLD |
